Keywords: DE; dextrose equivalent; DNS; 3,5-dinitrosalicylic acid; TAKA; Aspergillus oryzae α-amylase; L-DE5; DE5 maltodextrin obtained from the liquefaction of 10% starch; L-DE10; DE10 maltodextrin from the liquefaction of 10% starch; L-DE15; DE15 maltodextrin fr
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: anti-infectives; bioavailability; clinical pharmacokinetics; formulation; oral absorption; pharmacokinetics; HCV; hepatitis C virus; GT; genotype; DAA; direct-acting antiviral; RBV; ribavirin; GLE; glecaprevir; PIB; pibrentasvir; Cmax; maximum plasma conc
Keywords: CFTc; corrected carotid flow time; PLR; passive leg raise; RBV; relative blood volume; ROC; receiver operator curve; AUROC; area under receiver operator curve; LR; likelihood ratio; Hemodynamics; Blood volume; Renal dialysis; Ultrasonography; Doppler;
Keywords: Public procurement; Healthcare procurement; NHS; Value based procurement; Hermeneutics; RBV; Resource Based View; Aggregation;
Keywords: Strategy; Antitrust; Market power; RBV; Estratégia; Antitruste; Poder de mercado; RBV; Estrategia; Defensa de la competencia; Poder de mercado; RBV;
Keywords: HCV; hepatitis C virus; RNA; Ribonucleic Acid; RT-PCR; Reverse-transcriptase Polymerase Chain Reaction; DNA; Deoxyribonucleic Acid; IFN; interferon; RBV; ribavirin; PEG; pegylated; DAA; direct-acting antiviral; SVR; sustained viral response; Hepatitis C;
Keywords: Composite; Sustainable consumption and production; MBV; RBV; Performance; Third party logistics;
Keywords: MELD; model for end-stage liver disease; QOL; quality of life; LT; liver transplantation; IFN; interferon; RBV; ribavirin; HCC; hepatocellular carcinoma; eGFR; estimated glomerular filtration rate; SRTR; Scientific Registry of Transplant Recipients; HCV;
Keywords: Container Port; Competitiveness; Institutional Theory; RBV
Keywords: DAA; NS3/4A Protease Inhibitor; Nucleoside/Nucleotide; Non-nucleoside; DAA; direct-acting antiviral agent; DCV; daclatasvir; HCV; hepatitis C virus; HTA; host-targeted antiviral agent; IFN; interferon; ISG; interferon-stimulated gene; NI; nucleoside inhib
Keywords: HCV; hepatitis C; LT; liver transplantation; DDI; drug-drug interactions; DAAs; direct-acting antivirals; PegINF; peginterferon; RBV; ribavirin; MELD; model of end-stage liver disease; PI; protease inhibitor; PR; peginterferon plus ribavirin; SAEs; seriou
Keywords: Antecedents; Importer commitment; Importer-exporter relationships; RBV; The relational view;
Keywords: Marketing capability; Financial performance; Abnormal stock returns; Fama-French model; Retailing firms; Bootstrap data envelopment analysis; RBV;
Safety and Efficacy of Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection in Patients with β-Thalassemia Major
Keywords: DAA; Direct Acting Antiviral; DCV; Daclatasvir; ETR; End of Treatment Response; HCV; Hepatitis C Virus; PegINF-α; Pegylated Interferon-α; RBV; Ribavirin; RVR; Rapid Virological Response; SOF; Sofosbuvir; SVR12; Sustained Virological Response Post-treatm
Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy
Keywords: Hepatitis C; Relapse; Direct-acting antivirals; Neutralizing antibodies; Sustained virological response; E1E2 envelope; HCV; hepatitis C virus; DAA; direct-acting antiviral; SVR; sustained virological response; RBV; ribavirin; PEG-IFN; pegylated-interfero
The association of CCL3 and CCL4 polymorphisms with HCV clearance in Chinese Han population
Keywords: HCV; hepatitis C virus; SVR; sustained virologic response; pegIFN-α; pegylated interferon-α; RBV; ribavirin; SNPs; single nucleotide polymorphisms; WT; wild-type; GLU; glucose; GWAS; genome-wide association study; MIP-1α; macrophage inflammatory protei
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
Keywords: Direct-acting Antiviral; DAA; Short-duration; Pangenotypic; ALT; alanine aminotransferase; CI; confidence interval; DAA; direct-acting antiviral; G/P; glecaprevir/pibrentasvir; HCV; hepatitis C virus; IFN; interferon; ITT; intention-to-treat; LLOQ; lower
Pan-Genotype Hepatitis E Virus Replication in Stem Cell-Derived Hepatocellular Systems
Keywords: HLCs; Antiviral; Primary Isolates; Personalized Medicine; ALB; albumin; AFP; alpha-fetoprotein; bFGF; basic fibroblast growth factor; BM; basal medium; CsA; cyclosporine A; DE; definitive endoderm; DMSO; dimethyl sulfoxide; Dox; doxycycline; ESC; embryoni
True ileal phosphorus digestibility of monocalcium phosphate, monodicalcium phosphate and dicalcium phosphate for broiler chickens
Keywords: Ca; calcium; DM; dry matter; DMI; dry matter intake; GMD; geometric mean diameter; GSD; geometric standard deviation; P; phosphorus; RBV; relative bioavailability value; Broilers; Inorganic phosphates; Phosphorus; Regression method; True ileal digestibili
Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3 and 4: A Real Life Experience from India
Keywords: DAA; Direct Acting Antiviral; DCV; Daclatasvir; EASL; European Association of Study of the Liver (EASL); ETR; End of Treatment Response; HBV; Hepatitis B; HCC; Hepatocellular Carcinoma; HCV; Hepatitis C Virus; HIV; Human Immunedeficiency Virus; ITT; inten
Synthesis and biological evaluation of a library of hybrid derivatives as inhibitors of influenza virus PA-PB1 interaction
Keywords: Anti-Influenza; PA-PB1; RdRp; Amino acid coupling; SPPS; Diphenyl-pyridine; AcOEt; Ethyl acetate; CC50; Half maximal cytotoxic concentration; cRNA; complementar RNA; DCM; dichloromethane; DDQ; 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone; DIPEA; N,N-Diisopro
Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection
Keywords: MELD; BMI; Prognostic; Biomarker; ALT; alanine aminotransferase; AUROC; area under the receiver operative curve; BMI; body mass index; CI; confidence interval; CPT; Child-Pugh-Turcotte score; DAA; direct-acting antiviral; GFR; glomerulus filtration rate;
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals
Keywords: HCV; RASs; DAA; Virologic Treatment Failure; DAA; direct-acting antiviral; DCV; daclatasvir; EOT; end of treatment; GT; genotype; HCV; hepatitis C virus; LDV; ledipasvir; NS; nonstructural protein; PCR; polymerase chain reaction; PEG IFN; pegylated interf
The Mexican consensus on the treatment of hepatitis C
Keywords: Consensus; Direct-acting antiviral agents; Interferon-free regimens; Ribavirin; Consenso; Agentes antivirales de acción directa; RegÃmenes libres de interferón; Ribavirina; AASLD; American Association for the Study of Liver Diseases; AFP; alpha-fetopro
Consenso Mexicano para el Tratamiento de la Hepatitis C
Keywords: Consenso; Agentes antivirales de acción directa; RegÃmenes libres de interferón; Ribavirina; Consensus; Direct-acting antiviral agents; Interferon-free regimens; Ribavirin; AAD; antivirales de acción directa; AASLD; Asociación Americana para el Estud
Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing
Keywords: Chronic hepatitis C; DAA treatment; Immune response; miRNA-122; HCV; hepatitis C virus; IP-10; interferon gamma-induced protein; CHC; chronic hepatitis C; DAAs; direct acting antivirals; SVR; sustained virological response; miR-122; microRNA-122; RAS; res
Effectiveness and Tolerability of Direct Acting Antiviral Therapy for Hepatitis C in a Real World Elderly Cohort
Keywords: DAA; direct acting antiviral; HCV; hepatitis C virus; LDV; ledipasvir; RBV; ribavirin; SMV; simeprevir; SOF; sofosbuvir; SVR12; sustained virologic response;
Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning
Keywords: BN; Bayesian network; COMET; context-based modeling for expeditious typing; DAA; direct acting antiviral; dN/dS; ratio of non-synonymous and synonymous substitutions; DNA; deoxyribonucleic acid; e.g.; exempli gratia (for example); ePI; PI-exposure; FEL; f
Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT)
Keywords: HCV; hepatitis C virus; CHC; chronic hepatitis C; HCC; hepatocellular carcinoma; LT; liver transplantation; PEG-IFN; pegylated interferon; RBV; ribavirin; SVR; sustained virological response; ANRS; France REcherche Nord & sud Sida-HIV Hépatites-FRENSH; V
Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection
Keywords: Routine Clinical Practice; Direct-Acting Antiviral Agents; Cirrhosis; Genotype 4; DAA; direct-acting antiviral agent; EOT; end of treatment; GT; genotype; HCV; hepatitis C virus; LDV; ledipasvir; OMV; ombitasvir; PTV; paritaprevir; r; ritonavir; RBV; riba
Scanning and updating failure: How AT&T turned its political capability into a core rigidity
Keywords: Telecommunication; Lobbying; Political connections; Corporate political activity; Capabilities; RBV;
Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C
Keywords: CHC; chronic hepatitis C; HCV; Hepatitis C virus; PEG-IFN; pegylated interferon alfa; RBV; ribavirin; DAAs; direct-acting antiviral agents; GT1; genotype 1; GT4; genotype 4; IQR; inter-quartile range; OR; odds ratio; HCV; IL28B; Liver stiffness; Fibrosis
International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement
Keywords: HCV; hepatitis C virus; HCV-EHMs; HCV-extrahepatic manifestations; IFN; interferon; CV; cryoglobulinemic vasculitis; AVT; antiviral therapy; Peg-IFN; pegylated interferon; RBV; ribavirin; DAAs; direct-acting antiviral agents; FDA; food and drug administra
Polymorphisms of chemokine receptor genes and clearance of hepatitis C virus infection in Chinese population
Keywords: HCV; hepatitis C virus; PEG; pegylated; RBV; ribavirin; SNPs; single nucleotide polymorphisms; SVR; sustained virological response; HWE; Hardy-Weinberg equilibrium; ALT; alanine aminotransferase; AST; aspartate aminotransferase; AFP; alpha fetal protein;
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications
Keywords: ANRS CirVir; HCV Clearance; Direct Antivirals; Prognosis; AFP; α-fetoprotein; ANRS CO12 CirVir; Agence Nationale pour la Recherche sur le SIDA et les hépatites virales cohort 12 viral cirrhosis; BI; bacterial infection; CumI; cumulated incidence; DAA; d
Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis
Keywords: Antiviral Therapy; Direct-acting Antivirals; Liver Disease; Portal Hypertension; AUROC; areas under the receiver operating characteristic curve; CPT; Child-Pugh Turcotte; CPT-B; Child-Pugh Turcotte-stage B; CSPH; clinically significant portal hypertension
Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis
Keywords: PRO; Quality of Life; Direct-Acting Antivirals; DAA; CLDQ-HCV; Chronic Liver Disease Questionnaire-HCV Version; CPT; Child-Pugh-Turcotte; FACIT-F; Functional Assessment of Chronic Illness Therapy-Fatigue; HCV; hepatitis C virus; PRO; patient-reported outc
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection
Keywords: Hepatitis C; Randomized; Therapy; C-EDGE Treatment-Experienced; AE; adverse event; ALT; alanine aminotransferase; ART; antiretroviral therapy; CI; confidence interval; EBR; elbasvir; GT; genotype; GZR; grazoprevir; HCV; hepatitis C virus; HIV; human immun
Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection
Keywords: Genetics; Liver Cancer; Mutation; Metalloprotease; AFP; α-fetoprotein; anti-HBc; antibody to hepatitis B core antigen; BMP1; bone morphogenetic protein 1; CCl4; carbon tetrachloride; CDAA; choline-deficient L-amino acid-defined; CHC; chronic hepatitis C;
Finally, safe and effective treatment options for hepatitis C in hemodialysis patients
Keywords: HCV; hepatitis C virus; ESRD; end-stage renal disease; HD; hemodialysis; DAA; direct acting antivirals, SOF, sofosbuvir; SIM; simeprevir; LED; ledipasvir; DCV; daclatasvir; RBV; ribavirn; IFN; interferon; SVR; sustained virologic response; pk; pharmacokin
Research ArticleBoceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients
Keywords: MSM; men having sex with men; HCV; hepatitis C virus; AHCV; acute hepatitis C virus; PegIFN; pegylated interferon; SVR; sustained virological response; RBV; ribavirin; DAA; direct-acting antiviral; DAHHS; Dutch Acute HCV in HIV Study; cART; combination an
Research ArticleSustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12Â weeks
Keywords: HCV; hepatitis C virus; GT; genotype; SVR; sustained virologic response; SVR12; sustained virologic response 12Â weeks post-treatment; PegIFN; pegylated interferon; RBV; ribavirin; DAA; direct-acting antiviral; OBV; ombitasvir; PTV; paritaprevir; r; riton
Research ArticleModelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men
Keywords: HCV; Hepatitis C virus; PWLH; People who live with HIV; MSM; Men who have sex with men; DC; Decompensated cirrhosis; HCC; Hepatocellular carcinoma; PegIFN; Pegylated-interferon-α; RBV; Ribavirin; DAA; Direct acting antivirals; EASL; European Association
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis
Keywords: HCV; hepatitis C virus; DAA; direct-acting antiviral; MELD; model for end-stage liver disease; SVR; sustained virological response; EAP; expanded access programme; HCVRUK; hepatitis C Research UK; SOF; sofosbuvir; LDV; ledipasvir; DCV; daclatasvir; RBV; r
Research ArticleDaclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection
Keywords: HCV; hepatitis C virus; SMV; simeprevir; PegIFN; peginterferon; RBV; ribavirin; DCV; daclatasvir; ASV; asuneprevir; SVR; sustained virologic response; LLOQ; lower limit of quantitation; AE; adverse event; SVR12; sustained virologic response at posttreatme
IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection
Keywords: ALT; alanine aminotransferase; AST; aspartate aminotransferase; BMI; body mass index; cEVR; complete early virological response; CHC; chronic hepatitis C; CI; confidence interval; ETVR; end-of-treatment virological response; EVR; early virological respons
Research ArticlePrioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
Keywords: HCV; hepatitis C virus; PWID; people who inject drugs; PegIFN; pegylated interferon; RBV; ribavirin; IFN-free; interferon-free; DAA; direct-acting antiviral; HCC; hepatocellular carcinoma; QALY; quality adjusted life-year; NMB; net monetary benefit; ESLD;
Research ArticleEfficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials
Keywords: HCV; hepatitis C virus; GT; genotype; TPV; telaprevir; PegIFN; pegylated interferon; RBV; ribavirin; SVR; sustained virologic response; DAA; direct-acting antiviral agents; OBV; ombitasvir; PTV; paritaprevir; r; ritonavir; DSV; dasabuvir; IL28B; interleuk
Research ArticleClinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens
Keywords: SOF; sofosbuvir; CAP/CTM; COBAS AmpliPrep/COBAS TaqMan v2.0; ART; Abbott RealTime HCV test; GT; genotype; RBV; ribavirin; PegIFN; pegylated-interferon alfa; SMV; simeprevir; HCV; hepatitis C virus; SVR; sustained virological response; DAA; direct-acting a
Research ArticleHepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity
Keywords: HEV; hepatitis E virus; RBV; ribavirin; ALT; alanine aminotransferase; IU; international units; γGT; γ-glutamyltransferase; CLL; chronic lymphoid leukemia; NGS; next-generation sequencing; RdRp; RNA-dependent RNA polymerase; HVR; hypervariable region; O